AAAmado Andrés

Amado Andrés

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Amado Andrés has a total of 88 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cell-mediated and Neutralizing Antibody Responses to the SARS-CoV-2 Omicron BA.4/BA.5–adapted Bivalent Vaccine Booster in Kidney and Liver Transplant Recipients

    by Mario Fernández-Ruiz, Patricia Bsc Almendro-Vázquez, Natalia Redondo, Tamara Bsn Ruiz-Merlo, Sandra Clt Abella, Adán Clt Somoza, Francisco López-Medrano, Rafael San Juan, Carmelo Loinaz, Amado Andrés, et al.

    Background.: The immunogenicity elicited by the Omicron BA.4/BA.5–adapted bivalent booster vaccine after solid organ transplantation (SOT) has not been characterized. Methods.: We assessed cell-mediated and neutralizing IgG antibody responses against the BA.4/BA.5 spike receptor-binding domain at baseline and 2 wk after the administration of an mRNA-based bivalent (ancestral strain and BA.4/BA.5 subvariants) vaccine among 30 SOT recipients who had received ≥3 monovalent vaccine doses. Previous coronavirus disease 2019 history was present in 46.7% of them. We also recruited a control group of 19 nontransplant healthy individuals. Cell-mediated immunity was measured by fluorescent ELISpot assay for interferon (IFN)-γ secretion, whereas the neutralizing IgG antibody response against the BA.4/BA.5 spike receptor-binding domain was quantified with a competitive ELISA. Results.: The median number of BA.4/BA.5 spike–specific IFN-γ–producing spot-forming units (SFUs) increased from baseline to 2 wk postbooster (83.8 versus 133.0 SFUs/106 peripheral blood mononuclear cells; P = 0.0017). Seropositivity rate also increased (46.7%–83.3%; P = 0.001), as well as serum neutralizing activity (4.2%–78.3%; P < 0.0001). Patients with no prior coronavirus disease 2019 history experienced higher improvements in cell-mediated and neutralizing responses after booster vaccination. There was no correlation between BA.4/BA.5 spike–specific IFN-γ–producing SFUs and neutralizing activity. Nontransplant controls showed more robust postbooster cell-mediated immunity than SOT recipients (591.1 versus 133.0 IFN-γ–producing SFUs/106 peripheral blood mononuclear cells; P < 0.0001), although no differences were observed for antibody responses in terms of postbooster seropositivity rates or neutralizing activity. Conclusions.: Booster with the BA.4/BA.5–adapted bivalent vaccine generated strong subvariant-specific responses among SOT recipients. Booster-induced cell-mediated immunity, however, remained lower than in immunocompetent individuals.


  • Open Access

    Kidney transplantation in the extremely elderly from extremely aged deceased donors: a kidney for each age

    by Jimena Cabrera, Mario Fernández-Ruiz, Hernando Trujillo, Esther González, María Molina, Natalia Polanco, Eduardo Hernández, Enrique Morales, Eduardo Gutiérrez, Juan Rodríguez Mori, et al.

    Background: Advances in life expectancy have led to an increase in the number of elderly people with end-stage renal disease (ESRD). Scarce information is available on the outcomes of kidney transplantation (KT) in extremely elderly patients based on an allocation policy prioritizing donor–recipient age matching.Methods: We included recipients ≥75 years that underwent KT from similarly aged deceased donors at our institution between 2002 and 2015. Determinants of death-censored graft and patient survival were assessed by Cox regression.Results: We included 138 recipients with a median follow-up of 38.8 months. Median (interquartile range) age of recipients and donors was 77.5 (76.3–79.7) and 77.0 years (74.7–79.0), with 22.5% of donors ≥80 years. Primary graft non-function occurred in 8.0% (11/138) of patients. Cumulative incidence rates for post-transplant infection and biopsy-proven acute rejection (BPAR) were 70.3% (97/138) and 15.2% (21/138), respectively. One- and 5-year patient survival were 82.1 and 60.1%, respectively, whereas the corresponding rates for death-censored graft survival were 95.6 and 93.1%. Infection was the leading cause of death (46.0% of fatal cases). The occurrence of BPAR was associated with lower 1-year patient survival [hazard ratio (HR) = 4.21, 95% confidence interval (CI) 1.64–10.82; P = 0.003]. Diabetic nephropathy was the only factor predicting 5-year death-censored graft survival (HR = 4.82, 95% CI 1.08–21.56; P = 0.040).Conclusions: ESRD patients ≥75 years can access KT and remain dialysis free for their remaining lifespan by using grafts from extremely aged deceased donors, yielding encouraging results in terms of recipient and graft survival.


  • Pre‐transplant dialysis modality does not influence short‐ or long‐term outcome in kidney transplant recipients: analysis of paired kidneys from the same deceased donor

    by Teresa Dipalma, Mario Fernández‐Ruiz, Manuel Praga, Natalia Polanco, Esther González, Elena Gutiérrez‐Solis, Eduardo Gutiérrez, Amado Andrés

    Previous studies have reported contradictory results regarding the effect of pre‐transplant dialysis modality on the outcomes after kidney transplantation (KT). To minimize the confounding effect of donor‐related variables, we performed a donor‐matched retrospective comparison of 160 patients that received only one modality of pre‐transplant dialysis (peritoneal dialysis [PD] and hemodialysis [HD] in 80 patients each) and that subsequently underwent KT at our center between January 1990 and December 2007. Cox regression models were used to evaluate the association between pre‐transplant dialysis modality and primary study outcomes (death‐censored graft survival and patient survival). To control for imbalances in recipient‐related baseline characteristics, we performed additional adjustments for the propensity score (PS) for receiving pre‐transplant PD (versus HD). There were no significant differences according to pre‐transplant dialysis modality in death‐censored graft survival (PS‐adjusted hazard ratio [aHR]: 0.65; 95% confidence interval [95% CI]: 0.25–1.68) or patient survival (aHR: 0.58; 95% CI: 0.13–2.68). There were no differences in 10‐year graft function or in the incidence of post‐transplant complications either, except for a higher risk of lymphocele in patients undergoing PD (odds ratio: 4.31; 95% CI: 1.15–16.21). In conclusion, pre‐transplant dialysis modality in KT recipients does not impact short‐ or long‐term graft outcomes or patient survival.


  • Results of a Living Donor Kidney Promotion Program

    by E. González Monte, I. Delgado, N. Polanco, E. Hernández, T. Dipalma, A. Hernández, M. Castillo, E. Morales, M. Praga, J.M. Morales, et al.


  • Extended-Release Tacrolimus Therapy in De Novo Kidney Transplant Recipients: Single-Center Experience

    by A. Andrés, M. Delgado-Arranz, E. Morales, T. Dipalma, N. Polanco, E. Gutierrez-Solis, J.M. Morales, M. Praga, E. Gutierrez, E. Gonzalez


  • A Randomized Trial Comparing Renal Function in Older Kidney Transplant Patients Following Delayed Versus Immediate Tacrolimus Administration

    by Amado Andrés, Klemens Budde, Pierre-Alain Clavien, Thomas Becker, Michèle Kessler, Przemyslaw Pisarski, Paolo Fornara, Dirk Burmeister, Ronald J. Hené, Elisabeth Cassuto-Viguier

    This large, randomized, multicenter trial evaluated if basiliximab induction and delayed tacrolimus can preserve renal function in older kidney transplant patients. Patients aged 60 years and older received delayed tacrolimus with basiliximab and mycophenolate mofetil with early steroid discontinuation (Tac-d, n=132) or standard tacrolimus with mycophenolate mofetil and steroids until day 91 (Tac-s, n=122). Tacrolimus trough levels were 5 to 10 ng/mL after day 43 in both groups. Renal function at month 6 was measured by calculated creatinine clearance (Cockcroft-Gault formula). In both groups, mean recipient age was 66 years, mean donor age was 63 years with 73% of donors aged 60 years and older. Steroid discontinuation was slower than protocol specified. In the Tac-d group, 56.1% were steroid free at day 14 and 81.8% at month 6. In the Tac-s group, 37.7% were steroid free at month 4 and 63.9% at month 6. Mean (±SD) calculated creatinine clearance was 45.7±16.1 mL/min (Tac-d) and 45.0±18.2 mL/min (Tac-s) (P=ns), mean glomerular filtration rate (modified diet in renal disease formula) was 44.9±16.2 mL/min and 41.6±16.8 mL/min, respectively. Incidences of biopsy-proven acute rejection were 18.9% (Tac-d) and 18.0% (Tac-s). Delayed graft function was 30.3% (Tac-d) and 23.8% (Tac-s). Estimated patient survival rates (Kaplan-Meier) in the Tac-d and Tac-s groups were 96.1% vs. 99.2% and estimated graft survival rates were 90% vs. 87.6%, respectively. Safety results were similar with both regimens. Delayed tacrolimus with basiliximab induction did not provide an advantage in preserving renal function or reducing delayed graft function in older kidney transplant patients.


  • Lower Rate of Family Refusal for Organ Donation in Non–Heart-Beating Versus Brain-Dead Donors

    by A. Andrés, E. Morales, S. Vázquez, M.P. Cebrian, E. Nuño, T. Ortuño, J.M. Morales, E. Hernández, E. González, M.J. Gutiérrez, et al.


  • Kidneys From Elderly Deceased Donors Discarded for Transplantation

    by A. Andrés, N. Polanco, M.P. Cebrian, M. Sol Vereda, S. Vazquez, E. Nuño, T. Bello, E. Gutierrez, E. Gonzalez, M. Praga, et al.


  • A randomized trial of basiliximab with three different patterns of cyclosporin A initiation in renal transplant from expanded criteria donors and at high risk of delayed graft function

    by Amado Andrés, Roberto Marcén, Francisco Valdés, Jaime Sánchez Plumed, Ricard Solà, Pedro Errasti, Ricardo Lauzurica, Luis Pallardó, Jesús Bustamante, Juan José Amenábar, et al.

    Abstract:  This study assays therapy with basiliximab and different patterns of cyclosporin A (CsA) initiation in renal transplant (RT) recipients from expanded criteria donors (ECD) and at high risk of delayed graft function (DGF). A multicentre six‐month open‐label randomized trial with three parallel groups treated with basiliximab plus steroids, mycophenolate mofetil and different patterns of CsA initiation: early within 24 h post‐RT at 3 mg/kg/d (Group 1; n = 38), and at 5 mg/kg/d (Group 2; n = 40), or delayed after 7–10 d at 5 mg/kg/d (Group 3; n = 36). There were no differences among groups in six months GFR (43.1 ± 12, 48.0 ± 14 and 47.2 ± 17 mL/min, respectively), DGF (Group 1: 31%, Group 2: 37%, Group 3: 42%), nor biopsy‐proven acute rejection, although clinically treated and biopsy‐proven acute rejection was significantly higher in Group 3 (25%) vs. Group 1 (5.3%, p < 0.05). At six months no differences were observed in death‐censored graft survival or patient survival. Induction therapy with basiliximab and three CsA‐ME initiation patterns in RT recipients from ECD and at high risk of DGF presented good renal function and graft survival at six months. Late onset group did not achieve improvement in DGF rate and showed a higher incidence of clinically treated and biopsy‐proven acute rejection.


  • Efficacy and Safety of Valsartan, an Angiotensin II Receptor Antagonist, in Hypertension After Renal Transplantation: A Randomized Multicenter Study

    by A Andrés, E Morales, J M Morales, I Bosch, C Campo, L M Ruilope, Valsartan in Renal Transplantation Group